INTRODUCTION
Systemic immunoglobulin light-chain amyloidosis (AL) is the most common type of systemic amyloidosis with an estimated incidence of 8-10 cases per million person-years. 1, 2 Although there have been recent advances in AL, there is a major need for a framework for clinical research to encourage the development of new therapies. Access to novel agents and their optimal and safe use are challenges for patients with this rare disease. Well-designed clinical trials with multicenter collaboration will accelerate timely testing of novel agents and combinations, will improve access and will accelerate pharmaceutical company efforts and acceptance by payers. We in the United States are heartened by the continued interest and support of the National Cancer Institute study groups, particularly the Southwest and Eastern Oncology Groups, in developing phase II and III trials for patients with AL, and in the European Union by the collaboration of national plasma-cell disease networks and of the European Myeloma Network. These efforts should be complemented by the development of a phase I pipeline to nurture the development of phase II and III trials.
In this consensus report, we review distinctive aspects of AL that impact trial design, recent important advances in AL, the definitions of hematologic and organ response in AL and their implementation in clinical trials, the heterogeneity of the study populations among AL patients and the end points relevant to the design of clinical trials. We hope that our comprehensive detailed overview will serve to inform the design and implementation of collaborative clinical trials.
DISTINCTIVE FEATURES OF AL
The distinctive features of AL have significant implications for clinical trial design and drug development. AL involves monoclonal plasma cells productive of immunoglobulin light chains that misfold and directly cause organ toxicity and form amyloid deposits, leading to organ failure and death, often from cardiac involvement. 3 In some cases, the tempo of disease can be rapid with an interval of months between diagnosis and death. 4 Two-thirds of AL patients present with one or two major organ systems involved (heart, kidneys, liver/ GI tract, peripheral nervous system and soft tissues) while a third of patients presents with more than two systems involved. 2 Symptoms reflect involved organ disease. Both the clonal plasma cells and the pathologic light chain proteins are targets for therapy in AL.
Unlike multiple myeloma, morbidity and mortality in AL are due to the devastating effects of the toxic monoclonal protein not to the proliferation of monoclonal plasma cells. Nonetheless, therapies that eliminate monoclonal plasma cells (similar to those employed in multiple myeloma) ameliorate AL disease because they can remove the factory producing the toxic proteins. Most patients die of complications of cardiac dysfunction due to monoclonal light chains, and survival in AL depends upon rapid suppression of the synthesis of the monoclonal proteins and stabilization or recovery of heart function. 5, 6 The necessity to translate hematologic response into cardiac and other organ responses to improve quality of life (QOL) and extend survival requires the combined evaluation of both clonal and organ responses and raises several problems unique to AL. For example, although the hematologic response is a prerequisite for improving outcome, this is dependent upon the extent of the organ damage and its reversibility. Patients with very advanced cardiac damage at high risk of progressive heart failure and sudden death may not be rescued by effective anti-plasma cell therapy. Efforts should be made to identify these patients, representing up to 20% of the patients in referral centers, who should then be considered for alternatives such as orthotopic heart transplantation. 7 It is therefore necessary to stratify patients according to the extent of cardiac damage and prioritize appropriate investigational approaches. In AL unlike in myeloma, achieving a partial hematologic response or stable disease may not offer a clinical benefit as ongoing light chain production may result in further organ damage. Partial response (PR) should always be viewed in conjunction with organ response in the evaluation of treatment outcomes, and stable hematologic disease is not an innocuous category of response in AL because of the risk of organ-disease progression. This makes the concept of time-to-next therapy as a clinical research end point of limited utility, unlike in multiple myeloma.
RECENT ADVANCES IN AL
Definitive typing To diagnose amyloidosis, tissue biopsy of either an involved organ or a surrogate site (for example, abdominal fat) must demonstrate amyloid deposition by Congo red staining or by electron micrographic identification of pathognomonic fibrils. 8 Once the diagnosis of amyloidosis has been made, the clinician must determine the type of amyloidosis that is present. If the work-up reveals a monoclonal protein, then the type is most probably AL; however, the possible coexistence of a monoclonal gammopathy and hereditary or age-related systemic amyloidosis should always be considered. 9 If the work-up does not reveal a monoclonal gammopathy, then the AL type is unlikely and evaluation for other types should commence.
Transthyretin amyloidosis (ATTR) is next most common, caused by either mutant (hereditary) variants (ATTRm) or the age-related variant due to wild-type transthyretin (ATTRwt). 10 Secondary amyloidosis, a type associated with inflammation, although rare in the developed world, still occurs in association with autoimmune diseases, malignancies and chronic infections. Because clinical presentations are similar for the common types, one cannot infer the type of amyloid in a given patient. And because monoclonal gammopathies of undetermined significance are increasingly common with age, the possibility that a patient with amyloidosis may have two potential precursor proteins needs to be appreciated. 11 DNA sequencing of genes related to hereditary variants is useful after the type of amyloid has been identified both as confirmatory testing for the patient and as a key screening test for the patient's kindred. 9 Immunoelectron microscopy has proven to be more reliable than immunohistochemistry for typing amyloidosis. 12 Laser microdissection with mass spectrometry (LMD/MS) is a recent advance in diagnostic testing that identifies the type of amyloid with high reliability and accuracy. 13 An MS-based proteomic approach has also been developed for the direct analysis of the abdominal fat aspirate.
14 Amyloid tissue typing is specifically indicated in cases where two potential amyloid precursor proteins are present. Such cases include patients with monoclonal gammopathies who are African-American or elderly men, or who have dominant peripheral or autonomic neuropathy, family histories of amyloidosis or coexisting inflammatory disorders. African-Americans have higher rates of monoclonal gammopathies and a 4% incidence of the gene causing an ATTRm variant (Val122Ile). Elderly men also have higher rates of both monoclonal gammopathies and age-related ATTRwt. These patients almost always have one type of amyloid causing their disease which can be reliably identified using proteomic-based methods available at referral centers.
Free light chain measurements Serum free light chain (FLC) studies and serum and urine immunofixation are essential and, in conjunction with bone marrow immunohistochemistry (CD138, kappa and lambda), can establish clonality. Fluorescent in-situ hybridization to look for abnormalities associated with clonal plasma-cell diseases should be performed, and Congo red staining is necessary to identify amyloid. [15] [16] [17] Use of the FLC assay has significantly changed the way that patients with AL are diagnosed and monitored. 18 The serum FLC assay is critical for evaluating patients with AL, as many patients lack a measurable circulating intact immunoglobulin. 19 FLC levels and ratios are abnormal in 90% of AL patients, and the elevated FLC usually is the amyloid precursor protein. New criteria for response of the hematologic disease have been developed based on the FLC assay, and significant decreases in the pathologic or involved FLC (iFLC) are associated with better survival (Figure 1 ). 20 Although FLC measurement is a mainstay in the care of patients with AL, several analytical problems, such as lot-to-lot variation in immunoreactivity of individual monoclonal FLC, lack of linearity in dilution and high imprecision have been reported. 21 Given the vital role had by this assay in AL, clinicians and researchers should be aware of these limitations. We encourage support for a quality assurance program based on sample sharing within the national networks conducting phase III clinical trials in AL.
Cardiac biomarker staging Staging for cardiac involvement is also a critical part of the initial evaluation. The cardiac risk assessment model represents another recent advance that has helped to standardize the evaluation of AL patients. 22 The presence and character of cardiac involvement at diagnosis remains a major prognostic factor for all AL patients; indeed, it appears that all AL patients have a degree of cardiac involvement at diagnosis even if asymptomatic. 23, 24 Cardiac events are the most common cause of death in AL patients. Patients with cardiac involvement can present with fatigue, progressive dyspnea on exertion, diastolic dysfunction, left ventricular hypertrophy in the absence of hypertension or valvular disease, pericardial effusion, and low voltage on electrocardiogram. 25 The cardiac biomarkers N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 26 and troponin T (or I) 27 are prognostic with respect to survival in AL patients, and a system incorporating these biomarkers is currently in use, with patients Figure 1 . Patients in this international case series from seven centers were analyzed for survival at 3 months after beginning therapy based on metrics for hematologic response assessed at 6 months. In this series, 43.6% received oral melphalan and dexamethasone (MDex), 11.4% SCT, 22% immunomodulatory agentbased therapy and 3% bortezomib and dexamethasone. Response criteria are CR (immunofixation negative and FLC normal); very good PR (very good partial; reduction in the dFLC to o40 mg/l); PR (partial; reduction in the dFLC by 450%); and NR (no response; less than PR). 20 assigned to stage I, II or III based on the presence of 0, 1 or 2 of these biomarkers exceeding threshold levels with reported median survivals of 26.4, 10.5 and 3.5 months, respectively.
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Recent experience with this staging system on the phase III level has raised concerns about exclusion of stage III patients from trials when there may be a subset of stage III patients with better survival. Re-examinations of overall prognostic approaches to newly diagnosed patients continue to emerge, including ones that employ variables related to new cardiac biomarkers and to the plasma-cell disease in AL such as cyclin D1 expression levels in clonal plasma cells and the numerical difference between iFLC and uninvolved FLCs (Table 1) . 17, 23, 28 These retrospective efforts are particularly useful for the interpretation of phase II clinical trial results in the newly diagnosed when prognostic data are available but, as survival improves with new treatments and as new diagnostics become available, they must continue to be updated.
Anti-amyloid therapy Novel approaches have been recently developed targeting the amyloid deposits and promoting their reabsorption. Immunotherapeutic approaches that impair the capacity of misfolded iFLC to be toxic or to aggregate and form fibrils are currently in testing. Passive immunotherapy with a murine IgG1 anti-human light chain monoclonal antibody, designated as 11-1F4, which recognizes a conformational epitope present on generic amyloid fibrils but not on the soluble amyloidogenic precursor protein, represents one such approach to disease treatment. 29 Under an exploratory phase I investigational new drug exemption, the safety and biodistribution of 124I-m11-1F4 in AL patients has been determined. Organ-specific uptake in patient tissues has been demonstrated and the agent has been used for cardiac-gated acquisition of positron emission tomography imaging which may guide selection of patients for future immunotherapy using the chimerized or humanized form of this antibody.
In a mouse model of secondary amyloidosis, the clearance of amyloid deposits can be promoted by combining a small palindromic drug capable of clearing serum amyloid P-component from the blood stream followed by treatment with anti-serum amyloid P-component antibodies to opsonize fibrils for phagocytosis. 30 It is possible that this approach could be applicable to AL.
Recently, the tetracycline analog doxycycline has been shown to disrupt light chain fibrils in vitro and to reduce AL amyloid deposition in a transgenic mouse model of AL. 31 This class of compounds also warrants study in patients.
HEMATOLOGIC AND ORGAN RESPONSE CATEGORIES

Hematologic responses
Because AL has features of both a clonal hematologic disorder and a multisystem organ disease, the assessment of disease and response to therapy in AL is more complex than in multiple myeloma. Assessments of response to therapy must be objective and have validated links to clinical benefit such as functional improvement, progression-free survival (PFS) and overall survival (OS). Modern response criteria in AL grew out of the experience with autologous stem cell transplant (SCT) against the backdrop of criteria defining AL organ involvement and improvement with therapy. 32, 33 Because patients post-SCT frequently achieved profound complete hematologic responses with improved organ function, the objective scoring of hematologic and organ responses was deemed important in the 2005 consensus opinion of AL investigators. 34 Questions of validation were not addressed at that time and the criteria referred specifically to newly diagnosed patients.
With such questions in mind, investigators participating in the 2010 consensus committees of the XII International Symposium on Amyloidosis pooled 816 patients with systemic AL from 7 referral centers in the United States and European Union to refine and validate the criteria for hematologic and cardiac responses to treatment in newly diagnosed patients based on survival analyses. At this time, both hematologic and cardiac response criteria in newly diagnosed patients to initial therapy have had their relationship to OS validated in the 2010 consensus landmark analyses (Figures 1 and 2 ). 20 The basis for hematologic response assessment is the serum FLCs as measured by nephelometry. The cutoffs of FLC percent reduction and absolute values achieved with initial therapy that best predicted survival and death within 12 months were identified by means of a series of receiver operator characteristic curve analyses. 20 Measurements of the traditional M protein were Abbreviations: NT-proBNP, N-terminal prohormone of brain natriuretic peptide; cTnT, cardiac troponin T; hs-cTnT, highly sensitive cTnT; FLC-diff, the difference between the uninvolved free light chain subtracted from the involved free light chain measured by the serum FLC assay.
neither as comprehensive nor as useful as FLC measurements because the majority of AL patients do not have M proteins on serum or urine protein electrophoresis and because the iFLC cause the disease. In addition, even in the 17% of patients (135/816) with measurable M proteins at baseline surviving at 6 months after starting therapy, the M-protein response did not improve survival in those not attaining an FLC response. With deference to the needs of both statistical uniformity and standardization of response assessments on clinical trials of newly diagnosed patients, a difference between the iFLC and uninvolved FLC of 50 mg/l was defined as assessable or measurable for response. 20 The criterion using this difference, the difference between iFLC and uninvolved FLC (dFLC), covers about 85% of newly diagnosed AL patients. A 50% reduction in dFLC is considered as a PR, a reduction in the dFLC to o40 mg/l a very good PR, and normal FLC levels with a normal kappa/lambda ratio and negative serum and urine immunofixation studies an amyloid complete response (CR) (Figure 1 ). For the 15% of patients with AL and normal FLC or dFLC o40 mg/dl at baseline, standard criteria of response used in myeloma are available. M proteins 4500 mg/dl by electrophoresis are generally considered as assessable for response, and serum and urine immunofixation identify the monoclonal component in a high proportion of patients; in such cases, the full range of newly defined FLC response categories would not be available.
Newly diagnosed patients who do not achieve a response to initial therapy are categorized as non-responders and are viewed as refractory. Criteria for progression of both organ and hematologic disease were defined in the 2005 consensus opinion (Tables 2 and 3 ). With respect to the role of bone marrow examination in the definition of hematologic CR, although we agree that a bone marrow plasma-cell test for clonality is reasonable to confirm CR in patients on clinical trials, the 2010 consensus opinion, based on results in three dozen patients achieving CR with marrow examinations, did not support this requirement across the board. In the international series of 816 patients from 7 centers, staging cardiac biomarkers were available for 53% (432/816). Of these, 24% were stage 1 (both NT-proBNP p332 ng/l and cardiac troponin T (cTnT) p0.035 ng/ml or cTnI p0.1 ng/ml), 52% stage 2 (NT-proBNP 4332 ng/l or cTnT 40.035 ng/ml or cTnI 40.1 ng/ml), and 24% stage 3 (both NT-proBNP 4332 ng/l and cTnT 40.035 ng/ml or cTnI 40.1 ng/ml). In these survival curves, results for 377 patients with baseline NT-proBNP greater than or equal to 650 ng/l are shown according to NT-proBNP response or progression at 6 months. 20 Table 2 . Organ response and progression criteria
Organ
Response Progression Heart NT-proBNP response (430% and 4300 ng/l decrease in patients with baseline NT-proBNP X650 ng/l) or NYHA class response (X2 class decrease in subjects with baseline NYHA class 3 or 4)
NT-proBNP progression (430% and 4300 ng/l increase) a or cTn progression (X33% increase) or Ejection fraction progression (X10% decrease) Kidney 50% decrease (at least 0.5 g/day) of 24-h urine protein (urine protein must be 40.5 g/day pretreatment). Creatinine and creatinine clearance must not worsen by 25% over baseline 50% increase (at least 1 g/day) of 24-h urine protein to 41 g/ day or 25% worsening of serum creatinine or creatinine clearance Liver 50% decrease in abnormal alkaline phosphatase value Decrease in liver size radiographically at least 2 cm 50% increase of alkaline phosphatase above the lowest value Organ responses Organ disease that is considered to be quantifiable for response includes cardiac disease, renal disease with proteinuria, and hepatic disease (Table 2) . 34, 35 Amyloid cardiomyopathy leads to a concentric increase in ventricular wall thickness; however, change in mean wall thickness measured by echocardiogram has not yet been shown to be a useful clinical end point. Worsening left ventricular ejection fraction, while a harbinger of poor outcome, is not useful either. Other echocardiographic and cardiac magnetic resonance imaging approaches are being evaluated but are not ready to be incorporated into response assessment. The cardiac biomarkers NT-proBNP and troponin T and I have been used for staging and response assessment. Their use has been validated in patients treated with conventional 23,36-38 and high-dose chemotherapy. 36, 39 In the 2010 consensus analyses, biomarker criteria for clinical cardiac response and progression after initial therapy have been validated in newly diagnosed patients as shown in Figure 2 . This approach is a major achievement in the scoring of cardiac responses, considering that these biomarkers are easily available in all clinical chemistry laboratories and that they are well standardized worldwide. The occurrence of a biomarker response is clearly associated with improved survival. An appreciation of factors that potentially affect biomarker levels need to be kept in mind, as troponin and NT-proBNP levels can be altered by renal insufficiency or by measures that influence heart failure independent of the state of AL disease. 23 NT-proBNP can also become elevated in patients treated with immunomodulatory agents independent of other laboratory values and may signal worsening heart failure. 40 While metrics for other organ responses are in use, they have not been validated to the degree that cardiac responses have been (Table 2) . With respect to renal response, proteinuria (preponderant albuminuria) in a 24-h urine collection is a reliable measure as long as renal function is stable. Renal responses can lag 12-24 months behind hematologic responses or, like cardiac responses, can occur incrementally during the course of therapy. Responses of hepatic disease are assessed according to alkaline phosphatase (a marker of cholestasis) and liver size. However, hepatic markers may be influenced by diastolic heart dysfunction. There are no validated quantitative measures for peripheral sensorimotor or autonomic neuropathy or soft tissue or endocrine involvement. However, assessment of QOL and performance status are relevant quantifiable measures of clinical status and indirectly of overall physiologic response to treatment. It is reasonable to expect statistical concordance between changes in organ disease, QOL and performance status. For QOL, the SF36 has been used in AL and has been shown to reflect improvement with effective treatment. 41 Single-center case series depict the direct association between hematologic response and organ responses. 42 The parallel reduction of FLC and cardiac biomarkers is associated with extended survival. 23, 43 As a general rule, the deeper the hematologic response, the greater the likelihood of organ response. Occasionally, the achievement of a PR translates into a significant organ response, suggesting that the toxicity and fibrillar potential of the iFLC was dependent on a threshold concentration. The reverse has also been observed; that is, occasionally, patients achieving normalization of the FLC continue to experience organ damage as can happen in patients with baseline low-level iFLC and renal involvement. In such cases, it is often unclear whether the worsening renal function is due to a highly toxic iFLC, the impact of chronic proteinuria on tubular function, or both.
When there is dysynchrony in responses, for instance a PR with worsening organ disease, it likely means that the level of hematologic response is inadequate, or the extent of organ disease too profound, for an organ response to occur. 20 Such assessments are clinically and temporally complex and may challenge the judgment of even the most experienced research teams. Similar concerns apply to distinguishing progression of organ disease from adverse events linked to therapy.
In clinical trials, reporting of hematologic and organ response measures, including cardiac biomarkers, 24-h proteinuria, alkaline phosphatase, and orthostatic vital signs should be performed at specified regular intervals during therapy, usually with each cycle. The complex pathophysiology of AL argues for more innovative and rapid assessments of treatment efficacy to improve patient outcomes, particularly in the design of phase II trials. Baseline and end-of-study scoring that takes into account QOL and performance status may be particularly useful.
A further challenge to assessing outcomes in clinical trials for AL is the complexity of analyzing adverse events in patients with underlying organ dysfunction. Adverse events in AL clinical trials must be reported and graded according to standard criteria such as those developed by the NCI. Attribution to treatment or to disease relies upon an in-depth understanding of both manifestations of amyloidosis in general and in the specific patient. Clinical investigators should seek to identify and understand novel toxicities that may occur in patients with amyloid organ dysfunction. Such a systematic prospective approach is the clearest way to minimize the confounding effects of amyloidrelated organ disease on the assessment of treatment-related effects.
Recommendations:
(1) It is important to remember that the consensus hematologic and organ response criteria apply to newly diagnosed patients. Nevertheless, use of the response criteria for hematologic, cardiac and renal disease is reasonable in constructing end points for clinical trials of all phases in all study populations. hematologic responses may be related to some aspect of the therapy, particularly if there is evidence for such associations in other patient populations. Absent such evidence, the basis for the adverse event may be attributed to underlying AL organ disease. In phase I trials of novel agents developed specifically for amyloidosis or AL, the report of the patient and the evaluations of the center investigator, sponsor and regulatory agencies will determine the likelihood of an association with the novel agent.
STUDY POPULATIONS
Therapies for AL have historically been aimed at eliminating the clonal plasma cells producing the toxic precursor protein. 45 We define the major study populations as the newly diagnosed untreated, those who respond to initial therapy, and the relapsed/refractory, based on the hematologic parameter of FLC response. Moreover, the presence of cardiac stage III disease by biomarkers has become an exclusion criterion for phase III trials of initial therapy. This practice effectively creates two newly diagnosed study populations, those with or without advanced cardiac disease. Refractory hematologic disease is absence of hematologic response (less than a PR) to initial therapy. Lack of hematologic response increases risk of shortened survival.
Although absence of an organ response would appear to define it, refractory organ disease is more difficult to categorize. For example, patients with cardiac stage II or III disease can have an NT-proBNP biomarker response to initial therapy but remain stage II or III and continue to be at high risk of sudden death, and patients with proteinuria 420 g/day can have a renal response but still have proteinuria of 10 g/day. In both instances, the risks of sudden cardiac death or end-stage renal disease remain salient. Refractory organ disease then is defined as persistent significant organ disease causing symptoms despite prior therapy and best supportive care. Relapsed disease is progression of hematologic or organ disease after a response to initial therapy. Hematologic relapse often precedes progression of organ disease. In one series, only a quarter of patients without a hematologic CR after SCT remained stable without organ progression for 5 years. 46 Several phase II clinical trials in relapsed/refractory patients have been performed with immunomodulatory agents or the proteasome inhibitor bortezomib as single agents or in combination with alkylating agents and steroids with promising results. 45, [47] [48] [49] [50] However, the outcomes of these clinical trials are difficult to interpret because of the mix of patients with respect to disease status, prior initial therapy, extent of organ involvement and different ways of reporting results. For phase III studies in relapsed/refractory patients, stratification based on degree of organ disease is indicated. The design of such trials remains a challenge because there is no standard therapy for relapsed/ refractory AL, and therefore use of any regimen in the control arm is arbitrary.
Newly diagnosed patients who have achieved a PR or better with initial therapy are considered as responders. In AL, maintenance therapy with dexamethasone and a-interferon for a total of 5 years was planned following induction with pulse dexamethasone in patients enrolled on the Southwest Oncology Group S9628 trial but was tolerated poorly with 63% of patients experiencing grade 3 or 4 toxicities. 51 Adjuvant therapy with 9 months of thalidomide and dexamethasone following riskadapted SCT in patients who did not achieve CR resulted in hematologic responses in 71% of patients including 36% who achieved CR at 12 months post SCT. 52 In a similar trial, investigators used bortezomib and dexamethasone for six cycles following SCT, reporting an overall response rate of 96% with CR in 65% of patients. 53 Novel agents following initial therapy or SCT appear effective for AL, but uniform definitions of 'consolidation' and 'maintenance' are needed to design clinical trials and to develop standard practice guidelines. We define consolidation for patients achieving a response to initial therapy as treatment with non-cross resistant therapy administered with the goal of improving the hematologic response, while maintenance is therapy administered over a prolonged time (for example, 12 months or more) with the goal of prolonging PFS.
(1) We recommend that clinical trials be conducted for the following specific study populations in independent trials or as subgroups in trials: newly diagnosed untreated without advanced cardiac involvement; newly diagnosed untreated with advanced cardiac involvement; relapsed/refractory patients; and responders to initial therapy. Phase I trials at this time should be limited to patients with relapsed/refractory disease for whom no other standard therapy exists. In the current era, almost all patients will have been treated with alkylator-and proteasome-inhibitor-based therapy before being considered for phase I trials. 
TIME-TO-EVENT END POINTS
There are a number of time-to-event end points that are potentially relevant to AL clinical trials ( Table 4 ). The major caveat in this regard, however, is that hematologic response is intrinsically linked both to organ response and to survival and, given the rarity of AL, hematologic response remains a preferred primary end point for phase III trials with the notable exception of trials for patients with advanced cardiac involvement. OS is the most precise and reliable end point for trials in patients with the high mortality rate of advanced AL cardiac involvement, and also for trials testing therapies that may cause side effects associated with progressive organ dysfunction and may not therefore enhance survival.
In phase III trials, the utility of OS as the primary end point may be affected by the availability of effective agents as second-line therapy and by crossover trial designs. If OS is the primary end point in a phase III trial for newly diagnosed or relapsed/refractory patients, then those coming off-study on the less effective arm may achieve equivalent survival with novel investigational therapy or with crossover. Although this is currently less of a concern in AL than in myeloma, time-to-next-treatment (TNT) or PFS not OS may be useful primary end points for such trials and may better reflect the activity of the drug or schedule under study.
Although this argument is cogent, the limitations of TNT or PFS may be particularly problematic in chemotherapy trials for patients with AL. Those with a PR, for example, can have progression of organ disease and may need additional treatment in spite of a PR, and the hiatus required to make that clinical determination might be short but would fit TNT. With respect to PFS, patients with multiple organs involved who achieve hematologic and single organ responses but progression of other organ dysfunction would have a short PFS.
In chemotherapy trials then, assessing PFS should logically encompass assessment of both hematologic and organ diseases. In contrast, in trials of agents aimed at promoting resorption of amyloid deposits, PFS could be an important end point. Although it is unlikely that a single anti-amyloid agent would be used in patients with a persistent monoclonal iFLC component, it is possible that either PFS or OS could be the primary end point on the randomized phase II or phase III level.
Although TNT is a more liberal time-to-event end point, one possibly suited for phase III AL trials in relapsed/refractory patients, use of the TNT end point depends upon the judgment of the investigators and also assumes that a menu of therapies or trials ('next therapies') exist when in fact they do not. The era of phase I and I/II multicenter trials in AL has only just begun. Patients who have hematologic or organ progression, or a PR with stable but clinically morbid organ disease, may be offered additional empiric therapy depending on the experience and practice of their physician. Of note, the detection of persistent amyloid deposits in abdominal fat, bone marrow or involved organ is not an indication for further therapy since amyloid deposits can persist for years after functional recovery of the target organs.
(1) For phase III trials employing chemotherapeutic agents for newly diagnosed untreated patients without advanced cardiac involvement, hematologic response is a more appropriate primary end point than OS. We note that the exigencies of sample size, accrual time and standards of regulatory bodies with respect to new drug applications are factors that may influence the use of one or both of these as primary end points. In phase III trials, patients must be stratified based on the degree of cardiac involvement to balance the arms. (2) With respect to newly diagnosed patients with advanced cardiac involvement, new approaches that may prolong survival for these patients could be tested straightforwardly in phase III trials with OS as the primary end point. (3) Multicenter phase II trials are encouraged and we recommend strongly that time-to-event end points be routinely included as secondary end points in such studies to provide information for phase III trial design. (4) Both consolidation and maintenance should be explored in multicenter clinical trials in responders to initial therapy. The concepts of consolidation and maintenance can apply to chemotherapeutic agents and hematologic disease and also to anti-amyloid agents and organ disease. Phase II trials designed to measure the efficacy of consolidation regimens may employ improvement in hematologic response as their primary end point but should also report organ responses and OS, while maintenance trials can employ PFS as their primary end point. (5) For trials employing anti-amyloid strategies, time to progression of organ disease (PFS) and OS may be appropriate primary end points but it is difficult to ignore the importance of the monoclonal disease and therefore a compelling and substantial rationale must exist to limit or not permit chemotherapy within such trials. It is possible that these approaches will ultimately find a home as adjuncts to antiplasma cell approaches.
CONCLUSIONS
We have outlined a forward-looking framework for clinical research and drug development in systemic AL. In Europe, where national centers and networks dedicated to clonal plasma-cell diseases exist, the past few years have seen the emergence of a collaborative effort in phase II and III clinical trial development in AL, aided by pharmaceutical company involvement. In the United States, the cooperative groups have led trials in AL over the years but the time has come for them to collaborate directly and fully in trial development and adoption of study population and end point criteria.
Single-center phase I trials may have a place in drug development but, given the rarity of AL and the burden that travel places on sick patients, multicenter networks for the conduct of phase I trials are clearly needed. Such networks would provide opportunities for drug development among experienced clinical groups within standardized formats, making collaboration with interested pharmaceutical companies easier. The future success of clinical trial and drug development for AL requires collaboration among dedicated investigators in centers of excellence, along with conscientious and motivated referring physicians who seek clinical trials for their patients with AL and who support their patients' participation in them.
Employing novel agents approved for related diseases outside of the context of clinical trials will slow the process of identifying optimal dosing, schedule, and combinations for this unusual patient population. The potential for more favorable outcomes with combinations of chemo-and immuno-therapies makes collaboration and patient willingness to participate imperative to achieve the goal of cure. We hope that the approach we outline provides a timely and effective platform that proves to be of benefit to patients. 
